Permitted Research Sample Clauses

Permitted Research. Notwithstanding Section 2.7 to the contrary, if during the Term, Licensee approves the conduct of any research of a Competitive Product as proposed by the Inventors, such approval shall be set forth in a written agreement signed by Licensee and Licensor that sets forth in reasonable detail the scope of such research. Any such research shall be strictly non-commercial, and no Third Party shall have any rights in or to the results of such research. Licensor shall provide Licensee with semi-annual, written reports of planned experiments within the scope of the approved research and the results of completed experiment. The Parties agree that the provisions of this Section 2.8 do not require a further written approval by Licensee in connection with the conduct of the PhD Research by the PhD Student, and that in lieu of the semi-annual reports provided above in this Section 2.8, Licensor shall provide Licensee with a copy of the final results of the PhD Research, including a copy of the resulting thesis as submitted by the Student. Any publications related to such approved research or the PhD Research or the results thereof shall be subject to pre-publication review and delay on the terms provided in Section 6.4.
Sample 1Sample 2
AutoNDA by SimpleDocs
Permitted Research. Project 1: Assess the growth rate and transfectability of embryonic stem cells The goal of this project is to determine methods for reliable and repeatable genetic modulation of embryonic stem cells provided by the Sponsor, with the intent of producing genetically engineered cell lines. The project would involve conducting background work on the reagents and techniques commonly used to transfect hESCs. Genetic transfection would be conducted on two lines, to demonstrate robustness of technique. hESC lines would be amplified to produce sufficient quantities for experimental manipulations. Amplification will be conducted using one or more of the following conditions: mouse fibroblast feeder layers, conditioned media from mouse fibroblast feeder layers, human fibroblast feeder layers, conditioned media from human fibroblast feeder layers, or using conditions free from mouse or rodent feeder layers or conditioning. Amplified hESC lines would be transfected using lentiviral or adenoviral or adeno-associated viral systems. This will involve isolation or acquisition of human sequences to labeling genes, construction of vectors, growth of vectors, insertion of vectors in test cells that are not hESC lines, followed by insertion of vectors in hESC lines. Transfected lines would be assessed for growth rate, growth characteristics, and stability of gene insertion over multiple passages. This will involve passaging cells at standardized dilutions, measurement of cell quantity at standardized time points post-passaging, assessment of morphology at standardized time points post-passaging, and assessment of the percentage of cells expressing labeling genes at standardized time points post-passaging. This project Will last for 6 months. Budget: Personnel: $ 22,030 Equipment: $ 0 Travel $ 0 Animals and supplies: $ 9,450 Other: $ 0 Total direct costs: $ 31,480 Indirect: $ 16,055 GRAND TOTAL: $ 47,535
Sample 1

Related to Permitted Research

  • Permitted Activities The Executive shall devote his entire business time, attention and energies to the Business of the Employer and shall not during the Term be engaged (whether or not during normal business hours) in any other business or professional activity, whether or not such activity is pursued for gain, profit or other pecuniary advantage; but this shall not be construed as preventing the Executive from:

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Permitted Activities of Holdings Holdings shall not:

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Market Activities The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.

  • Permitted Business The Facility Lessee shall not engage in any business or activities other than the lease, operation, maintenance and marketing and sale of the output, fuel or other products from, or relating or incidental to, the Facility leased by the Facility Lessee. Notwithstanding any of the foregoing the Facility Lessee may not change the nature of its business.

  • Sales Material To the knowledge of the Company, all materials provided by the Company or any of its affiliates to the Dealer, including materials provided to the Dealer in connection with its due diligence investigation relating to the Offering, were materially accurate as of the date provided.

  • SALES MATERIALS 4.1 LIFE COMPANY will furnish, or will cause to be furnished, to TRUST and ADVISER, each piece of sales literature or other promotional material in which TRUST or ADVISER is named, at least ten (10) Business Days prior to its intended use. No such material will be used if TRUST or ADVISER objects to its use in writing within seven (7) Business Days after receipt of such material.

  • Development Services Licensee may from time to time wish to augment the RMSS product with additional functionality or utility, or to integrate it with Licensee systems from other sources, and for such purposes may request the provision of development services from RMSS.

  • Clinical Development (a) Stellartech shall design, develop and construct a Clinical Unit for each of the Thermage Disposable Device and the Thermage Generator, and any required component or subassembly thereof and shall deliver such Clinical Units to Thermage in accordance with the Development Program; (b) Stellartech shall deliver to Thermage such other Deliverables as are contemplated by the Development Program in accordance with the Development Program; and (c) as requested by Thermage and automatically at the conclusion of the Development Program, Stellartech, so long as Thermage is not in breach of its material obligation hereunder, shall deliver in writing to Thermage any and all data and information held by or in the control of Stellartech which is necessary or useful to obtain regulatory approval of the Products in the United States or any foreign country.

Time is Money Join Law Insider Premium to draft better contracts faster.